Overview
PneumoWave is a digital therapeutics company headquartered in the United Kingdom and the United States. Specializing in real-time respiratory depression monitoring, the company is known for its development of innovative wearable biosensor technology. PneumoWave aims to capture and analyze patient data to enable timely interventions in life-threatening conditions, with a significant focus on opioid dependence and mental illness management through a virtual-first approach. The company was founded in 2018, originally known as Altair Medical, and is part of a rapidly growing market expected to reach 178 million users by 2030.
Key Developments and Achievements
PneumoWave has raised £7.5 million in a Series A funding round, intended to accelerate clinical validation and regulatory submission for its respiratory change diagnosis and monitoring platform. Further financial backing has brought its total funding to $12.21 million over two funding rounds. Significant milestones include achieving ISO 13485:2016 certification and registering a version of its technology as a UKCA Class 1 device, affirming its commitment to high standards in medical device quality management systems. The company collaborates with institutions like King’s College London in initiatives aimed at reducing drug-related deaths.
Leadership Team
- Dr. Bruce Henderson: Co-Founder and Chief Medical Officer, offers extensive experience as a forensic physician and has spearheaded successful healthcare ventures, guiding PneumoWave's strategic direction and clinical integration.
- Richie Bavasso: President, a recognized global life sciences entrepreneur, focuses on digital innovation strategies. His strategic role is pivotal in establishing a strong presence in the US.
- Stuart Kelly: Chief Technology Officer, dedicated to developing PneumoWave's wearable respiratory monitoring technology. His background as a chartered mechanical engineer merges technical expertise with product design.
- Dr. Osian Meredith: Chief Scientific Officer, integrates an entrepreneurial mindset to translate scientific insights into commercial technologies.
Business and Product Offering
PneumoWave's core technology encompasses an integrated respiratory monitoring platform with small, chest-worn biosensors for continuous data capture and advanced analytics. This innovation is geared toward the early detection of potential respiratory distress, emphasizing improved care for vulnerable populations with its products like the DCM activity monitor and ALERT for real-time monitoring of opioid-induced respiratory depression.
Financial Snapshot
- Total Funding: $12.21 million
- Revenue: Approximately $2.4 million annually
- Employees: 31
- Key Focus: Real-time remote respiratory monitoring with pending patents in the US and UK
Locations
- UK Office: PneumoWave, LTD, Second Floor, Suite 3 and 4, Maxim Office Park, Eurocentral ML1 4WQ, UK
- US Offices:
- 4900 O’Hear Avenue, Suite 100, PMB# 511, North Charleston, SC 29405, USA
- 421 Fayetteville Street, Suite 1100, Raleigh, NC 27601, USA
Key Competitors
1. Click Therapeutics
Specializes in digital therapeutics as prescription medical treatments via software. Focuses on combining neuroscience with software to develop Software-Enhanced Drugs™ targeting multiple conditions.
- Funding: $52 million Series B financing.
- Growth: Expanding into diverse therapeutic areas including mental health, obesity, and cardiometabolic conditions.
2. RelieVRx (AppliedVR)
An FDA-authorized virtual reality system for chronic lower back pain management developed by AppliedVR.
- Offering: Non-invasive, in-home pain management through cognitive behavioral therapy (CBT)-based VR.
- Market Position: Leading VR-based treatments for chronic conditions.
3. HelloBetter
An online mental health therapy provider via digital therapeutics, leading in digital mental health research.
- Coverage: Programs are DiGA-certified in Germany, fully covered by insurance.
- Target Conditions: Stress, burnout, sleep disorders, panic attacks.
- Expansion: US market presence with the HelloGina brand for sexual wellness.
4. Sweetch
Utilizes AI and emotional intelligence for personalized digital therapeutics for chronic condition management.
- Platform: Behavioral science-driven, aiming for long-term behavioral change.
- Strategy: Hyper-personalization to achieve behavioral goals and improve clinical outcomes.
5. Vorvida
A digital therapy for alcohol use disorder, providing tailored and private interventions.
- Efficacy: Proven to reduce alcohol consumption through web-based programs.
- Market Approach: Licensed by Orexo for US commercialization, focusing on alcohol use disorder with a user-friendly platform.
Market Insights
The digital therapeutics market is competitive and rapidly expanding, with PneumoWave positioned among key AI-driven innovations in respiratory monitoring. Opportunities for differentiation lie in leveraging real-time data and patient-centric platforms. An emphasis on innovation and securing additional funding can bolster growth and market penetration.
